IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PSC who wrote (844)	5/13/1997 1:27:00 PM
From: I. Luttichuys	of 1762

Hello PSC, I didn't mean to imply, naturally, that one of any two extremes is desirable. Tumour shrinkage is, of course, important and of primary concern to any physician. What I meant to get across is that given the possibility of similar efficacies among treatment options, the physician may want to know, from the patient's perspective, what option provides the best rate of tumour shrinkage with the least impingement as to the patient's lifestyle. This not to say that a patient's "sense of well-being" is more important than tumour shrinkage at all but, is simply to say that if tumour shrinkage rates are similar, physicians may want to then put some additional emphasis on what a patient finds bothersome and not bothersome about particular treatments. Hopefully time will tell whether prolonged well-being, which as you point out must include prolonged tumour response, will be seen in patients using C2B8. As you know IDEC's C2B8 does shrink tumours and does so with little discomfort to the patient as compared to many current treatment options. Sorry for any misunderstanding about the point I was trying to make... BENNETT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next